
Evommune Inc (EVMN) Stock Forecast & Price Target
Evommune Inc (EVMN) Analyst Ratings
Bulls say
Evommune is poised for success with their promising pipeline products, including EVO756 and EVO301, and a current valuation of $42 per share which is largely driven by the potential success of EVO756. The potential for the drug to be used in multiple conditions, such as migraine, greatly increases its revenue potential and the success of EVO301 in its Phase 2b study offers further promise for the company's future financial performance.
Bears say
Evommune is a clinical-stage biotechnology company with a focus on developing therapies for chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's pipeline products, EVO756 and EVO301, show promise in targeting the MRGPRX2 pathway, and initial clinical data suggest target engagement and potential efficacy in these diseases. However, the company faces risks such as competition from established drugs and the possibility of unexpected safety issues. Additionally, the company's financials are heavily reliant on the success of its clinical programs, which could lead to downside risk if they do not meet expectations.
This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.
Evommune Inc (EVMN) Analyst Forecast & Price Prediction
Start investing in Evommune Inc (EVMN)
Order type
Buy in
Order amount
Est. shares
0 shares